TREM2-SYK signaling controls microglial survival, plaque association, phagocytosis, and disease-associated microglial state transitions. The biology remains strong, but standalone TREM2 agonism in broad early Alzheimer's disease is weakened by recent clinical failure; future use should be stage-specific, biomarker-enriched, or combined with amyloid or tau-directed therapy.
No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for TREM2; yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TREM2; SYK.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.